Breast cancer in men.
Most men with breast cancer present with a mass in the breast, the evaluation of which should include a tissue diagnosis. If the presence of invasive cancer is established, adequate local therapy includes total removal of the breast. Most tumors are hormone-receptor positive. In high-risk patients, the use of endocrine adjuvant therapy and/or combined endocrine and chemotherapy should be considered. Patients with estrogen-receptor (ER)-negative disease should be offered chemotherapy. In patients with metastatic disease and ER-positive tumors, initial treatment should be endocrine therapy; systemic chemotherapy should be used in patients who are either hormone-receptor negative or resistant to available endocrine therapies.
Buzdar
Aman U
AU
Department of Breast, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018567:Breast Neoplasms, Male / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011960:Receptors, Estrogen; D012307:Risk Factors
D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen